1. Lidocaine transdermal patches reduced pain intensity in neuropathic cancer patients already receiving opioid treatment
- Author
-
Jui-Hung Tsai, I-Ting Liu, Pei-Fang Su, Ying-Tzu Huang, Ge-Lin Chiu, Yu-Yeh Chen, Wei-Shu Lai, and Peng-Chan Lin
- Subjects
Neuropathic pain ,Transdermal patch ,Cancer pain ,Numerical rating scale ,Analgesic ,Special situations and conditions ,RC952-1245 - Abstract
Abstract Background Limited efficacy has been observed when using opioids to treat neuropathic pain. Lidocaine patches reduce neuropathic pain in postherpetic neuralgia, but their benefits for cancer-related neuropathic pain remain unclear. This study aimed to investigate a treatment for cancer-related neuropathic pain. Methods We conducted a prospective, open-label, single-arm study to assess the efficacy and safety of lidocaine transdermal patches in patients experiencing localized, superficial, neuropathic cancer pain. Terminal cancer patients already receiving opioid treatment participated in the 3-day study. The primary endpoint was pain intensity evaluated by the numerical rating scale (NRS). The secondary endpoints were the pain relief score and the quality of analgesic treatment. Results The results showed a significant difference in the median NRS over 3 days (Kruskal–Wallis test, p
- Published
- 2023
- Full Text
- View/download PDF